Although the general PAH population showed increased endostatin plasma levels, the mutation carriers (N/D104ES) had significantly lower endostatin levels and better survival then non-mutation carriers (D/D104ES) [41]. This evidence concerns the gene COL18A1 and pulmonary arterial hypertension.